ELECSYS PROLACTIN ASSAY
Report
- Report Number
- 1823260-2018-00666
- Event Type
- Malfunction
- Date Received
- March 7, 2018
- Date of Event
- January 9, 2018
- Report Date
- March 20, 2018
- Manufacturer
- ROCHE DIAGNOSTICS
- Product Code
- CFT
- PMA / PMN Number
- K964748
- Removal / Correction Number
- NA
- Product Problem
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- GM
- Reporter Occupation
- HEALTH PROFESSIONAL
Narratives
EXPIRATION DATE WAS UPDATED. THE CUSTOMER BEGAN TO QUESTION THE PROLACTIN III RESULTS WHEN THEY SWITCHED FROM THE COBAS 8000 E 602 MODULE TO THE E801 MODULE. A METHOD COMPARISON WAS PERFORMED BETWEEN A COBAS E801 MODULE AND AN E602 MODULE AT THE INVESTIGATION SITE. REAGENT LOT 172258 WAS USED WITH THE E801 MODULE AT THE INVESTIGATION SITE. CALIBRATION AND QC WERE ACCEPTABLE. THE CUSTOMER SUBMITTED THE 40 PATIENT SAMPLES FOR INVESTIGATION. THE RESULTS FROM THE INVESTIGATION SHOW EXCELLENT COMPARABILITY BETWEEN THE E602 MODULE AND E801 MODULE. BASED ON THE INVESTIGATION RESULTS, A GENERAL REAGENT ISSUE CAN BE EXCLUDED. THE INVESTIGATION WAS UNABLE TO FIND A DEFINITIVE ROOT CAUSE.
THIS EVENT OCCURRED IN (B)(6). (B)(4).
THE CUSTOMER IS QUESTIONING RESULTS FOR MULTIPLE PATIENTS TESTED FOR ELECSYS PROLACTIN II (PROLACTIN II) ON A COBAS E801 MODULE. THE CUSTOMER COLLECTED 40 PATIENT SAMPLES THAT HAD BEEN TESTED ON THE E801 MODULE AND REPEATED THE SAMPLES BY THE ABBOTT ARCHITECT METHOD. BASED ON THE DATA PROVIDED, THE RESULTS FOR 23 PATIENT SAMPLES WERE DISCREPANT. THE INITIAL RESULTS FROM THE E801 MODULE HAD BEEN REPORTED OUTSIDE OF THE LABORATORY. REFER TO THE ATTACHED DATA FOR PATIENT RESULTS WITH GENDER AND AGE. THERE WAS NO ALLEGATION THAT AN ADVERSE EVENT OCCURRED. THE E801 MODULE SERIAL NUMBER WAS NOT PROVIDED.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 165796 | ELECSYS PROLACTIN ASSAY | RADIOIMMUNOASSAY, PROLACTIN (LACTOGEN) | CFT | ROCHE DIAGNOSTICS | NA | 172258 |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | 61 YR |